AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, … Read more
AmCad BioMed Corporation - Asset Resilience Ratio
AmCad BioMed Corporation (4188) has an Asset Resilience Ratio of 55.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how AmCad BioMed Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down AmCad BioMed Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $U0.00 | 0% |
| Short-term Investments | $U346.62 Million | 55.66% |
| Total Liquid Assets | $U346.62 Million | 55.66% |
Asset Resilience Insights
- Very High Liquidity: AmCad BioMed Corporation maintains exceptional liquid asset reserves at 55.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
AmCad BioMed Corporation Industry Peers by Asset Resilience Ratio
Compare AmCad BioMed Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for AmCad BioMed Corporation (2021–2025)
The table below shows the annual Asset Resilience Ratio data for AmCad BioMed Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.66% | $U346.62 Million | $U622.70 Million | +5.59pp |
| 2024-12-31 | 50.07% | $U347.95 Million | $U694.87 Million | -0.18pp |
| 2023-12-31 | 50.25% | $U257.61 Million | $U512.65 Million | -0.99pp |
| 2022-12-31 | 51.24% | $U283.80 Million | $U553.86 Million | +0.48pp |
| 2021-12-31 | 50.76% | $U312.54 Million | $U615.75 Million | -- |